3d42d97d12
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
33 lines
No EOL
1.3 KiB
Markdown
33 lines
No EOL
1.3 KiB
Markdown
# Oral Wegovy (Semaglutide Pill)
|
|
|
|
**Type:** GLP-1 receptor agonist, oral formulation
|
|
**Manufacturer:** Novo Nordisk
|
|
**Status:** FDA approved January 2026
|
|
**Indication:** Weight management in adults with obesity or overweight + ≥1 comorbidity; cardiovascular event risk reduction in adults with CVD + obesity/overweight
|
|
|
|
## Clinical Profile
|
|
|
|
**OASIS 4 Trial (Phase III, 64 weeks, n=307):**
|
|
- Weight loss: 16.6% with oral Wegovy + lifestyle intervention vs. 2.7% placebo
|
|
- Serious adverse events: 3.9% treatment vs. 8.8% placebo (lower in treatment arm)
|
|
- Common adverse reactions: nausea, vomiting, diarrhea
|
|
- Efficacy comparable to injectable formulation for this population
|
|
|
|
## Safety Label
|
|
|
|
- **Boxed warning:** Thyroid C-cell tumor risk (standard GLP-1 class warning)
|
|
- **NO eating disorder warning** in label
|
|
- **Suicidal behavior/ideation warning REMOVED** in 2026 FDA review (no causal link found)
|
|
- No eating disorder screening requirement in prescribing information
|
|
|
|
## Market Significance
|
|
|
|
- First oral GLP-1 formulation for weight management
|
|
- Eliminates injection barrier, expanding addressable patient population
|
|
- Manufacturing at North Carolina facilities
|
|
- Launched January 2026
|
|
|
|
## Timeline
|
|
|
|
- **2026-01-01** — FDA approval for weight management and cardiovascular risk reduction
|
|
- **2026-01-01** — Commercial launch with North Carolina manufacturing |